With highly selective inhibitors now in hand for the three major pro-survival family members, namely BCL-2, BCL-XL and MCL-1, cancer researchers and clinicians can rapidly expose the vulnerabilities of multiple cancer types and explore the efficacy of BH3 mimetics not only as single agents but also in combination with each other or with other targeted and conventional agents. Here, BCL2L1 is linked to cancer.